Mounjaro CDSCO alert lists six KwikPen batches in India as not of standard quality

Six batches of Mounjaro KwikPen sold in India appear in the Mounjaro CDSCO alert for September 2026, one batch for each strength on the market. All six entries record a failed assay test, and two batches also failed sterility testing. For patients, pharmacies and clinics, the practical question is which pens on the shelf are affected and what the listing does and does not say.

What the September alert lists

The Central Drugs Standard Control Organisation, India's drug regulator, publishes a monthly list of samples that state and central laboratories have tested and found not of standard quality. The September 2026 list holds 330 such entries plus one entry in a separate section for spurious drugs, as The South First reported on October 26. Six of those entries concern Mounjaro KwikPen, the multi dose pen form of tirzepatide from Eli Lilly, and together they span every strength of the pen sold in the country. According to the report, the batches were made by Eli Lilly Italy SPA and brought into India by the company's local arm. The rest of the list runs from antibiotics and drip fluids to thyroid tablets, cough syrups and cosmetics.

Every one of the six entries records a failure on assay, the test that checks how much active ingredient a product holds against its specification. The batch at the lowest strength also failed sterility testing, and the batch at the second strength failed sterility as well as a check for related substances, which looks for impurities. One entry, for a higher strength batch, is worded differently and does not state outright that the sample failed. The alert gives no measured values, so it is not possible to say how far any sample strayed from the standard. Sterility matters most for an injected medicine, because a pen that is not sterile can carry microbes straight under the skin.

What the listing means for patients and pharmacies

A listing of this kind names specific batches, not a whole product. The finding applies to the samples that a laboratory drew and tested, and other batches of the same pen are not covered by it. That difference matters for anyone who already holds a box at home. The batch number is printed on the carton and on the pen label, and a pharmacist can compare it with the public list. Patients should not stop or change treatment on their own, and the safer step is to call the pharmacy that dispensed the pen and the doctor who prescribed it. Pharmacies, in turn, will want to check stock against the listed batches before the next fill goes out.

Patients should not stop or change treatment on their own, and the safer step is to call the pharmacy that dispensed the pen and the doctor who prescribed it.

The report carried no statement from Lilly, and the Mounjaro CDSCO alert does not say whether the company has been asked to withdraw stock, whether a recall is under way, or whether Lilly accepts the results. Those are the facts a pharmacy needs before it acts, and they were not public when the alert was reported. An alert is a record of laboratory findings; on its own it is not a recall notice. Until more detail appears, the careful reading is narrow. Six named batches failed one or more tests at a government laboratory, and the rest of the supply has not been called into question by this list. Readers can follow pens, plants and shortages on our supply desk as the story develops.

Mounjaro supply in India and the wider alert

Lilly launched Mounjaro in India in March 2025, according to the same report, and doctors there prescribe it for type 2 diabetes and for weight management in eligible adults. Tirzepatide acts on two gut hormone receptors, GIP and GLP 1, which help control blood sugar and appetite. The six listed batches cover the full dose ladder, from the starting strength to the highest one, so the finding is not limited to people at one stage of treatment. Someone stepping up from one strength to the next could meet a listed batch at any point. For Mounjaro supply in India, that makes a batch check at each refill a more useful habit than a single check at the start of treatment.

The Mounjaro entries sit inside a long list. The same September alert names diabetes, blood pressure and thyroid tablets, several antibiotics, injectable fluids and cough syrups. Among the injectables, ceftriaxone products were flagged for particulate matter, clarity or content, and peritoneal dialysis solutions failed a bacterial endotoxin test. One amoxycillin and clavulanate tablet was declared spurious by a laboratory, and five cosmetics went over the legal mercury limit. Seen against that list, the Mounjaro CDSCO alert reflects routine monthly sampling rather than a targeted action against one company. Even so, sterility findings on an injectable pen used every week stand out from the tablets and syrups around them, and they deserve a clear answer from the importer.

What the alert does not tell us

The table below sets out what is known from the alert as reported. The gaps deserve as much attention as the entries. The alert names the tests that failed but gives no figures, so it does not show whether a sample held slightly less active ingredient than allowed or far less. It also does not say when the samples were drawn, in which states, or whether they came from pharmacies, hospitals or distributors. Those details shape the risk for any one patient, and none of them appeared in the public report. Anyone tracking the Mounjaro CDSCO alert should look for a follow up statement from Lilly India or from the regulator before drawing wider conclusions about the pen.

There is also a gray market risk to watch. When a branded injectable faces a quality question, some buyers turn to unofficial channels, online sellers or imported pens with no Indian paper trail. That route removes the batch traceability that made this alert possible, and it raises the chance of fake or badly stored product. Our gray market coverage tracks those channels without naming sellers. The safer course is to stay with licensed pharmacies, keep each carton with its batch number, and report any reaction or defect to the prescriber and to the national pharmacovigilance programme. Payers and hospital buyers in India may also want written assurance from the importer on the batches they hold.

Conclusion

The Mounjaro CDSCO alert lists six Mounjaro KwikPen batches, one per strength, with assay failures in all six and sterility failures in two, but gives no test values and no recall details. People using the pen in India can ask a pharmacist to check the batch number and should speak to their prescriber before changing treatment. The next step to watch is a statement from Lilly India or from the regulator.